Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market buy | 03/03 | 03/04 | 25 sh | $174.54 | $4,363.5 | +0.1% |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 25/08/22 | 01/20 | 400 sh | $163.72 | $65,488 | −1.7% |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 25/08/18 | 25/08/20 | 800 sh | $157.60 | $126,080 | −3.2% |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 25/08/07 | 25/08/08 | 400 sh | $150.04 | $60,016 | −1.6% |
Charles River Laboratories InternationalCRL | Open-market sale10b5-1 plan | 25/05/15 | 25/05/16 | 140 sh3 trades | $137.57avg. | $19,260.48 | −2.4% | |
Charles River Laboratories InternationalCRL | Open-market sale10b5-1 plan | 25/05/14 | 25/05/15 | 140 sh5 trades | $140.74avg. | $19,702.9 | −2.4% | |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 25/05/13 | 25/05/15 | 500 sh | $145.41 | $72,705 | −2.5% |
James C. FosterChairman, President and CEO | Charles River Laboratories InternationalCRL | Open-market buy | 25/02/20 | 25/02/21 | 6,075 sh | $165.01 | $1,002,435.75 | +3.4% |
Birgit GirshickCorporate Executive VP & COO | Charles River Laboratories InternationalCRL | Open-market buy | 25/02/20 | 25/02/21 | 1,514 sh | $164.63 | $249,249.82 | +2.8% |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 25/02/20 | 25/02/21 | 4,400 sh | $162.50 | $715,000 | −18.0% |
Charles River Laboratories InternationalCRL | Open-market sale | 24/11/07 | 24/11/12 | 7,621 sh3 trades | $216.17avg. | $1,647,418.25 | No record | |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 24/08/08 | 24/08/12 | 1,780 sh | $199.36 | $354,860.8 | −7.3% |
James C. FosterChairman, President and CEO | Charles River Laboratories InternationalCRL | Open-market sale10b5-1 plan | 24/08/01 | 24/08/05 | 25,000 sh | $250.00 | $6,250,000 | −11.7% |
Michael Gunnar KnellCSVP&Chief Accounting Officer | Charles River Laboratories InternationalCRL | Open-market saleAmendment | 24/03/08 | 24/05/29 | 808 sh | $267.52 | $216,156.16 | −9.4% |
Charles River Laboratories InternationalCRL | Open-market sale10b5-1 plan | 24/05/15 | 24/05/16 | 332 sh3 trades | $235.62avg. | $78,225.37 | −5.4% | |
Joseph W. LaPlumeEVP, Corp Strategy & Develop | Charles River Laboratories InternationalCRL | Open-market sale | 24/05/10 | 24/05/14 | 1,304 sh | $226.97 | $295,968.88 | −5.3% |
Michael Gunnar KnellCSVP&Chief Accounting Officer | Charles River Laboratories InternationalCRL | Open-market sale | 24/03/08 | 24/03/11 | 808 sh | $267.52 | $216,156.16 | −10.3% |
Charles River Laboratories InternationalCRL | Open-market sale | 24/03/04 | 24/03/05 | 2,750 sh2 trades | $261.05avg. | $717,890 | −26.0% | |
Charles River Laboratories InternationalCRL | Open-market sale | 24/02/29 | 24/03/04 | 3,786 sh2 trades | $253.45avg. | $959,544.98 | −34.7% | |
Victoria L. CreamerEVP & Chief People Officer | Charles River Laboratories InternationalCRL | Open-market sale | 24/02/29 | 24/03/01 | 5,000 sh | $253.70 | $1,268,500 | −27.0% |